Paper · 42958602
Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation.
Gorecki L. Exp Hematol Oncol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation. Papers, record 42958602. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42958602
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation.
- Journal
- Exp Hematol Oncol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-31
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NW24J-03-00005 | Ministerstvo Zdravotnictví Ceské Republiky | PubMed | ||
| DZRO-FVZ22-ZHN II | Ministerstvo Obrany České Republiky | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References498
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28,575,464 | Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. | Neuro Oncol | 2017 | https://conductscience.org/library/papers/28575464 | PubMed |
| 2 | 29,415,991 | Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29415991 | PubMed |
| 3 | 38,445,445 | Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial. | Cancer Biol Med | 2024 | https://conductscience.org/library/papers/38445445 | PubMed |
| 4 | 27,306,666 | Clinical trial of blood-brain barrier disruption by pulsed ultrasound. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/27306666 | PubMed |
| 5 | 32,641,768 | Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. | Nat Commun | 2020 | https://conductscience.org/library/papers/32641768 | PubMed |
| 6 | 29,022,921 | Current progress in the derivation and therapeutic application of neural stem cells. | Cell Death Dis | 2017 | https://conductscience.org/library/papers/29022921 | PubMed |
| 7 | 20,718,706 | Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. | Curr Cancer Drug Targets | 2010 | https://conductscience.org/library/papers/20718706 | PubMed |
| 8 | 31,350,295 | The Tumor Microenvironment Innately Modulates Cancer Progression. | Cancer Res | 2019 | https://conductscience.org/library/papers/31350295 | PubMed |
| 9 | 26,364,181 | Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. | Neuroradiology | 2015 | https://conductscience.org/library/papers/26364181 | PubMed |
| 10 | 35,031,058 | EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35031058 | PubMed |
1 to 10 of 498
See all 498 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42958602
GET https://conductscience.org/api/papers/v1/42958602/references?page=2